<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004654</url>
  </required_header>
  <id_info>
    <org_study_id>199/11799</org_study_id>
    <secondary_id>YALESM-8191</secondary_id>
    <nct_id>NCT00004654</nct_id>
  </id_info>
  <brief_title>Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with
      hereditary hemorrhagic telangiectasia.

      II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and
      gastrointestinal bleeding in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized study. One group of patients is treated with soy
      protein isolate for 12 weeks. The control group receives a placebo for 12 weeks.

      Patients cross to the alternate group following a 4-week washout.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1996</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Hereditary Hemorrhagic Telangiectasia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>soy protein isolate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following:

          -  First-degree relative with HHT

          -  History of recurrent epistaxis or gastrointestinal bleeding

          -  Three or more skin telangiectasia

          -  Migraine headache meeting International Headache Society criteria 3 or more times a
             month for more than 1 year

          -  No pattern of daily headaches

          -  No severe head trauma

          -  No onset of headaches after 50 years of age

          -  At least 1 month since migraine prophylaxis

          -  At least 1 month since any of the following medications: Beta blockers; Calcium
             channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin
             re-uptake inhibitors

          -  Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed

          -  Creatinine no greater than 2.5 g/dL

          -  No allergy to soy

          -  No pregnant women

          -  No women with intent to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua R. Korzenik</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>hereditary hemorrhagic telangiectasia</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

